Therefore, in ER+ breast cancer, the downregulation of K18 leads to the disinhibition of LRP16 nuclear action and the continuous activation of the ERα signaling pathway, to promote the growth and proliferation of breast cancer cells. Here, KRT18 is linked to breast cancer.